<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829114</url>
  </required_header>
  <id_info>
    <org_study_id>10079</org_study_id>
    <nct_id>NCT00829114</nct_id>
  </id_info>
  <brief_title>Interactions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs)</brief_title>
  <official_title>Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RHRU National Office, University of Witwatersand, Johannesburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, comparative study (1:1 allocation) to study interactions between
      nevirapine-containing antiretroviral therapies and combined oral contraceptive pills.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation as determined by weekly blood progesterone (P) measurement</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy as detected by monthly urine pregnancy testing</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) recording</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ART/COC group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COC group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETHINYL ESTRADIOL AND LEVOGESTREL</intervention_name>
    <description>30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETHINYL ESTRADIOL AND LEVOGESTREL</intervention_name>
    <description>30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to provide informed consent

          -  Willing to take COCs and follow all study requirements

          -  Has regular menstrual cycles every 21-35 days (when not taking hormonal contraception)

          -  Last menstrual period (LMP) &lt;35 days before study entry

          -  Has body mass index of 18-30

          -  Negative urine pregnancy test as enrollment

          -  Documented HIV-1 infection

          -  On nevirapine-containing ART for at least three months (ART group only)

          -  CD4 cell count of greater than or equal to 350 (for non-ARV group only)

          -  Currently sexually active and plans to stay sexually active for the next 6 months

        Exclusion Criteria:

          -  Medical contraindications to COC use

          -  Recent pregnancy (within 3 months)

          -  Has breastfed in last 3 months

          -  Last pregnancy was ectpoic

          -  Has been sterilized

          -  Has had any of the following conditions since last pregnancy, or since menarche if
             never pregnant:

        Pelvic Inflammatory disease Diagnosis of infertility

          -  Has had DMPA within 6 months or NET injectable within 3 months of study entry (or has
             had no menses since last injection regardless of its timing)

          -  has taken other hormonal therapies besides COCs (e.g., combined injectables, progestin
             implants or intrauterine systems, progestin-only contraceptive pills,
             medroxyprogesterone acetate, hormone replacement therapy) within 30 days of study
             entry

          -  Has an acute infection or other opportunistic diseases requiring therapy within 14
             days before enrollment

          -  Has active drug or alcohol use that, in the opinion of the investigator, would
             interfere with adherence to study requirements

          -  Has taken any prohibited medication within 30 days before study entry

          -  Has chronic diarrhea, malabsorption or inability to maintain an adequate oral intake

          -  Has any condition (social or medical) which in the opinion of the investigator would
             make study participation unsafe or complicate data interpretation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kavita Nanda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vera Halpern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>, RHRU National Office, University of Witwatersand</name>
      <address>
        <city>Esselent St. Hillbrow</city>
        <state>Johannesburg</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makerere University Medical School, Mulago Hospital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>October 28, 2011</last_update_submitted>
  <last_update_submitted_qc>October 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AE</keyword>
  <keyword>AIDS</keyword>
  <keyword>ALT</keyword>
  <keyword>ART</keyword>
  <keyword>AST</keyword>
  <keyword>DCF</keyword>
  <keyword>DMC</keyword>
  <keyword>FDA</keyword>
  <keyword>GCP</keyword>
  <keyword>HB sAg</keyword>
  <keyword>ICH</keyword>
  <keyword>IND</keyword>
  <keyword>IRB</keyword>
  <keyword>IU</keyword>
  <keyword>mg</keyword>
  <keyword>mm3</keyword>
  <keyword>PCR</keyword>
  <keyword>SAE</keyword>
  <keyword>ULN</keyword>
  <keyword>WB</keyword>
  <keyword>COC</keyword>
  <keyword>Combined Oral Contraceptives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

